Research compounds
Ecnoglutide
XW003 / Long-Acting GLP-1
A novel long-acting GLP-1 receptor agonist in development that showed promising weight loss results in Phase 2 trials. Designed for monthly or extended-interval dosing.
Also known as: XW003
- Status
- Ecnoglutide is in Phase 2 clinical trials and not approved.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- Extended (under investigation)
- How it's taken
- Subcutaneous injection (monthly potential)
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- GLP-1
How Ecnoglutide works
Activates GLP-1 receptors similar to semaglutide, but with structural modifications that dramatically extend its duration of action, potentially allowing monthly instead of weekly dosing.
What research has looked at
- Monthly dosing potential (fewer injections)
- Strong weight loss in early trials
- Similar mechanism to proven GLP-1 drugs
- Improved convenience and adherence
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Nausea and GI effects (typical of GLP-1 class)
- Vomiting
- Diarrhea
- Still being evaluated
- Long-term safety unknown
Sources
- Active clinical trials for ecnoglutide XW003 · U.S. National Library of Medicine
- PubMed research on ecnoglutide GLP-1 long acting · NIH · National Library of Medicine
- DrugBank record for ecnoglutide · DrugBank
Track Ecnoglutide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Ecnoglutide FAQ
What is Ecnoglutide?
A novel long-acting GLP-1 receptor agonist in development that showed promising weight loss results in Phase 2 trials. Designed for monthly or extended-interval dosing.
How does Ecnoglutide work?
Activates GLP-1 receptors similar to semaglutide, but with structural modifications that dramatically extend its duration of action, potentially allowing monthly instead of weekly dosing.
Is Ecnoglutide FDA approved?
No. Ecnoglutide is in Phase 2 clinical trials and not approved. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Ecnoglutide?
Reported half-life: Extended (under investigation).
How is Ecnoglutide taken?
Subcutaneous injection (monthly potential).
What side effects have been reported with Ecnoglutide?
Reported in the sources: Nausea and GI effects (typical of GLP-1 class); Vomiting; Diarrhea; Still being evaluated; Long-term safety unknown.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.